BrightGene Bio Medical Technology C (688166) - Cash Flow Conversion Efficiency

Latest as of June 2023: 0.011x

Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has a cash flow conversion efficiency ratio of 0.011x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.70 Million ≈ $3.91 Million USD) by net assets (CN¥2.35 Billion ≈ $344.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is BrightGene Bio Medical Technology C worth for the company's overall valuation and market capitalisation.

BrightGene Bio Medical Technology C - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how BrightGene Bio Medical Technology C's cash flow conversion efficiency has evolved over time, based on yearly financial data.

BrightGene Bio Medical Technology C Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BrightGene Bio Medical Technology C ranked by their cash flow conversion efficiency. Explore cash flow quality index of BrightGene Bio Medical Technology C to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	-0.014x
The Andersons Inc NASDAQ:ANDE	0.359x
Douzone Bizon Co Ltd KO:012510	0.036x
Cadeler A/S NYSE:CDLR	0.025x
Ebos Group Ltd AU:EBO	0.017x
Y.H. Dimri Construction & Development Ltd TA:DIMRI	-0.148x
Billerud AB ST:BILL	0.023x
Greatek Electronics Inc TW:2441	0.062x

Annual Cash Flow Conversion Efficiency for BrightGene Bio Medical Technology C (2016–2024)

The table below shows the annual cash flow conversion efficiency of BrightGene Bio Medical Technology C from 2016 to 2024. View latest BrightGene Bio Medical Technology C stock price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.44 Billion ≈ $356.66 Million	CN¥245.56 Million ≈ $35.93 Million	0.101x	+25.06%
2023-12-31	CN¥2.42 Billion ≈ $353.77 Million	CN¥194.77 Million ≈ $28.50 Million	0.081x	-41.98%
2022-12-31	CN¥2.24 Billion ≈ $328.03 Million	CN¥311.26 Million ≈ $45.55 Million	0.139x	+37.34%
2021-12-31	CN¥1.74 Billion ≈ $254.86 Million	CN¥176.08 Million ≈ $25.77 Million	0.101x	-6.82%
2020-12-31	CN¥1.43 Billion ≈ $209.63 Million	CN¥155.43 Million ≈ $22.74 Million	0.108x	+132.28%
2019-12-31	CN¥1.31 Billion ≈ $192.15 Million	CN¥61.33 Million ≈ $8.98 Million	0.047x	-43.58%
2018-12-31	CN¥772.85 Million ≈ $113.09 Million	CN¥63.99 Million ≈ $9.36 Million	0.083x	+3.25%
2017-12-31	CN¥446.02 Million ≈ $65.27 Million	CN¥35.77 Million ≈ $5.23 Million	0.080x	-40.63%
2016-12-31	CN¥220.15 Million ≈ $32.21 Million	CN¥29.73 Million ≈ $4.35 Million	0.135x	--

About BrightGene Bio Medical Technology C

SHG:688166 China Biotechnology

Market Cap

$2.28 Billion

CN¥15.57 Billion CNY

Market Cap Rank

#5780 Global

#1096 in China

Share Price

CN¥36.81

Change (1 day)

+1.52%

52-Week Range

CN¥29.53 - CN¥72.50

All Time High

CN¥116.49